The case for & against
Bull & Bear analysis
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a leading innovator in diabetes management, focusing on advanced insulin delivery solutions that aim to enhance the quality of life for individuals with diabetes. The company is well recognized for its flagship product, the T-Slim X2 insulin pump, and has made significant strides in integrating cutting-edge technology into its offerings, such as Control IQ automation. Tandem is currently expanding its market presence through a strategic shift towards a pharmacy benefit model and direct-to-consumer sales approaches, particularly in the rapidly evolving Type 2 diabetes management segment.
Bull says
- ↑Q1 2026 revenue of $247M (+7% YoY) with 29K pumps shipped
- ↑Gross margin improved to 55%, delivering $5M free cash flow
- ↑Mobi Tubeless integration aims to double addressable Type 2 market
- ↑Pharmacy PAYGO model to improve affordability, deepen engagement and margins
- ↑Healthy liquidity and strong balance sheet support growth initiatives
- ↑23 analysts rate buy, $28.88 average price target
Bear says
- ↓Supplier capacity constraints causing persistent supply chain bottlenecks
- ↓Negative profitability metrics and weak EPS revision trends raise red flags
- ↓PAYGO transition compliance issues yield only 5% pharmacy orders
- ↓Intensifying competition from Insulet, Medtronic and Dexcom may pressure pricing
- ↓Market resistance to new tech like Mobi Tubeless risks slower adoption
- ↓High short interest and weakening momentum underscore vulnerability
Investment themes with TNDM
Devices and instruments for medical treatment
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- this quarter's performance, we continued the momentum from last year by achieving new first quarter records for pump shipments and sales, as well as robust margin improvement and solid cash generation.
- We are reaffirming our annual 2026 guidance as we continue to execute on our bold business model transformation in both the U.S. and international markets.
- We set new first quarter records with more than 29,000 pump shipments worldwide and 247 million in sales.
Bear points
- it looks like new starts were down slightly year-over-year in Q1 and down modestly, sequentially by our math.
- This reflects the headwind of approximately 1 million from the adoption of PAYGO, as well as slight pressure in infusion set sales due to a key supplier shortages.
- In the second quarter, we expect that international sales will be approximately 80 million. This steps down from the first quarter due in part to the delayed impact of 3 to 4 million headwinds associated with our Go Direct transition.